According to Endoro, estimated $ 1 billion from market, industrial enzymes, biodegradable materials, alternative proteins and pharmaceuticals, they depend on the genetically engineered microbial to produce these compounds.
PeterFounder and CSO of Enduro Genetics say: “Cell-to-cell biomenufacturing challenges have been resolved for decades of academia and industry. Many companies were limited to the fact that a minority cells used today contribute to high production of a minority cells used in the biopics. In Endoro, we are giving new definitions with a new optimization technology to unlock the full potential of biotechnology, which we already use to enhance the very high-performance processes. This fund helps sustainable scales to accelerate our clients and commercialization and make meaningful changes to industries that affect all of ourThe “
Despite the best efforts to optimize genetic strains, large-scale industrial processes create situations that drive to convert micro organisms, creating “cell-to-cell variation”, because cells prioritize their survival rather than producing. These non-productive cells prolong, exceeds productive cells for space and nutrients, until all productive cells are gone. It causes a significant drop-off on the production cycle, affects profitability and reduces efficiency.
Enduro’s patent “synthetic addiction” technology, microbial production host integrates a genetic plug-in in the microbial production host, combined with its health and development. It ensures that only high-producing cells can survive and achieve success, effectively remove non-manufacturing cells from the population.
Enduro senses applies to all expression systems where production organisms or product types provide burdens on microbial hosts and can be used in new processes under established processes as well as development. It enables Enduro customers to produce more efficiently existing products and enable innovation by accelerating the development and commercialization of the new product line.
The startup has already calculated clients including biomeinufacturing leaders both biomedorm and food, agriculture and industrial places. The new funds take the total to $ 18 million raised by Enduro, which will be used to extend the Anduro technology platform and accelerate commercialization.
Romaine Souratrau, Supernova investment director says: “Enduro’s novel technology can act as an important capacity to break the barrier to the cost of bioscolation for huge enforcement in food and chemical industries. We also fascinated the traction of the team not only with technology, but also in the short time of bringing this team to the top biomonufacturing companies. We are hoping to work closely with Christian and Peter to support their journey to their growthThe “
Theis MalmbergThe general partner of the Venture in the afternoon says: “We are delighted to double our investment in Enduro in their series this round. Enduro Cell Re -Programming Technology is resolving big challenges in the Bioproving Space and large companies have already begun to cut the benefits. We believe that the party will have an external impact on the future of biomonufacturing and we are pleased to be part of that journey with them.“
[publish_date
